Vaccines Articles
GlaxoSmithKline (GSK) has receivedU.S. Food and Drug Administration approval for its Shingrix vaccine to prevent shingles (herpes zoster) in patients 50 years and older.
A clinical trial comparing the protective efficacy in older adults of a quadrivalent recombinant influenza vaccine with a standard-dose, egg-grown quadrivalent inactivated influenza vaccine during the A/H3N2-predominant 2014-2015 influenza season showed RIV4 provided better protection against confirmed influenza-like illness among older adults.
A new study shows that microneedle patches provide an alternative to conventional needle-and-syringe immunization, potentially offering improved immunogenicity, simplicity, cost-effectiveness, acceptability and safety.
A study conducted at the University of British Columbia found that mothers are viewed negatively if their child hasn’t been vaccinated, regardless of the reason.
A new study conducted at the Boston Medical Center is the first to support new recommendations for a two-dose HPV vaccine to prevent genital warts in kids younger than 15 years old.
Results of a new clinical trial show that the bacillus Calmette-Guerin vaccine could permanently reverse advanced type 1 diabetes in mice.
A new study conducted by the Centers for Disease Control and Prevention shows that during the years 2010 through 2014, the influenza vaccine reduced the risk of flu-associated death by half among children with underlying high-risk medical conditions and by nearly two-thirds among healthy children.
Study results from the division of oncology at University Hospital Basel in Switzerland show that patients treated with PD-1/PD-L1 checkpoint inhibitors may be at an increased risk for adverse events after receiving the seasonal influenza vaccination.
A new study shows newborns of pregnant women who have gotten their pertussis booster vaccine are far less likely to get
the disease than other babies.
A new vaccine to protect against rotavirus has been developed by Serum Institute of India.
Researchers at the Moffitt Cancer Center are developing a new vaccine that will help early-stage breast cancer patients who have HER2 positive disease.
Results of a Phase II clinical trial ofPfizer’s preventive vaccine againstClostridium difficile (C. diff) showed the vaccine was safe and stimulated a C. diff targeted immune response.
